Indium (111In) biciromab
Monoclonal antibody | |
---|---|
Type | Fab' fragment |
Source | Mouse |
Target | Fibrin II, beta chain |
Clinical data | |
Trade names | FibriScint |
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(what is this?) (verify) |
Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]
References
[edit]- ^ King DJ, Adair JR (March 1999). "Recombinant antibodies for the diagnosis and therapy of human diseases". Current Opinion in Drug Discovery & Development. 2 (2): 110–7. PMID 19649936.
- ^ "Centocor Ortho Biotech Products, L.P." Answers.com.
- ^ "Centocor withdraws imaging agent applications". DiagnosticImaging.com.